Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.
Feelders
Richard A
RA
de Bruin
Christiaan
C
Pereira
Alberto M
AM
Romijn
Johannes A
JA
Netea-Maier
Romana T
RT
Hermus
Ad R
AR
Zelissen
Pierre M
PM
van Heerebeek
Ramona
R
de Jong
Frank H
FH
van der Lely
Aart-Jan
AJ
de Herder
Wouter W
WW
Hofland
Leo J
LJ
Lamberts
Steven W
SW
D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000652:urine; D007654:Ketoconazole / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D047748:Pituitary ACTH Hypersecretion / Q000188:drug therapy* / Q000652:urine; D011446:Prospective Studies; D017448:Receptors, Dopamine D2; D017481:Receptors, Somatostatin / Q000037:antagonists & inhibitors; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D018491:Dopamine Agonists; D004873:Ergolines; D017448:Receptors, Dopamine D2; D017481:Receptors, Somatostatin; D013004:Somatostatin; C094573:somatostatin receptor 5; C517782:pasireotide; D000077465:Cabergoline; D007654:Ketoconazole; D006854:Hydrocortisone